Short answer
Prime Medicine, Inc. (PRME) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$49M
- +5.3% YoY
- EPS (diluted)
- −$0.28
- +30.0% YoY
Source: XBRL data from the Prime Medicine, Inc. (PRME) Q1 2026 10-Q on SEC EDGAR. USD.
Prime Medicine, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No material changes to risk factors since the December 31, 2025 Form 10-K
- Carried-forward risks include clinical development and regulatory approval uncertainty
- Carried-forward operational risk includes dependence on advancing Prime Medicine’s pipeline
- Carried-forward financial risk includes continued need for capital to fund operations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Prime Medicine, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.